Nebojsa Janjic, PhDChief Science Officer at SomaLogic, Inc.
Nebojsa Janjic has been CSO at SomaLogic since 2009 developing a new generation of aptamers for biomedical applications. Prior to SomaLogic, Dr. Janjic was co-founder and CSO at Replidyne, a company developing new antibiotics, and NeXstar Pharmaceuticals, the original aptamer company. His contributions include early development of Macugen, the first aptamer and the first VEGF inhibitor approved for the treatment of macular degeneration. Dr. Janjic received bachelor's degree in molecular biology and Ph.D. in physical organic chemistry from University of Washington in Seattle and completed postdoctoral training at Scripps Research Institute in La Jolla as Cancer Research Institute Fellow.